Clinical Trial Update: Long-term Administration Study of SND 919 Tablets in Parkinson's Disease [Phase 3]

View source ↗

Summary

Boehringer Ingelheim's Phase 3 long-term administration study of SND 919 tablets in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• SND 919 tablets

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Parkinson Disease | Phase 3 | Status: COMPLETED